Children with congenital hyperinsulinism
Conditions
Brief summary
Adverse events
Detailed description
Total amount of gastric carbohydrates administered (nasogastric [NG] tube or gastrostomy) to treat hypoglycemia, Time to removal of NG tube or gastrostomy, Time to pancreatic surgery (sub-total or total pancreatectomy), CGM percent time <70 mg/dL (3.9 mmol/L), Rate of CGM-detected hypoglycemia episodes <70 mg/dL (3.9 mmol/L) for 15 minutes or more, Rate of clinically significant CGM-detected hypoglycemia episodes <54 mg/dL (3.0 mmol/L) for 15 minutes or more
Interventions
DRUGDasiglucagon 4 mg/ml
Sponsors
Zealand Pharma A/S
Eligibility
Sex/Gender
All
Age
0 Years to 17 Years
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Adverse events | — |
Secondary
| Measure | Time frame |
|---|---|
| Total amount of gastric carbohydrates administered (nasogastric [NG] tube or gastrostomy) to treat hypoglycemia, Time to removal of NG tube or gastrostomy, Time to pancreatic surgery (sub-total or total pancreatectomy), CGM percent time <70 mg/dL (3.9 mmol/L), Rate of CGM-detected hypoglycemia episodes <70 mg/dL (3.9 mmol/L) for 15 minutes or more, Rate of clinically significant CGM-detected hypoglycemia episodes <54 mg/dL (3.0 mmol/L) for 15 minutes or more | — |
Countries
Germany
Outcome results
None listed